The coronavirus vaccine developed by Bharat Biotech, Covaxin, has been approved by the World Health Organization (WHO) under its emergency use listing (EUL) process.
The vaccine has thus far only been approved in a handful of countries, including Iran, Mexico, Greece and Nepal.
The decision from the WHO means that travelers vaccinated with Covaxin will be able to enter the USA, under new rules due to come into force on November 8.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze